1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Chronic Kidney Disease (CKD) Drugs Market
2.2. Global Chronic Kidney Disease (CKD) Drugs Market, By Drug Class, 2023 (US$ Million)
2.3. Global Chronic Kidney Disease (CKD) Drugs Market, By Geography, 2023 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2023

3. Chronic Kidney Disease (CKD) Drugs Market: Competitive Analysis
3.1. Market Positioning of Key Chronic Kidney Disease (CKD) Drugs Market Vendors
3.2. Strategies Adopted by Chronic Kidney Disease (CKD) Drugs Market Vendors
3.3. Key Industry Strategies
4. Chronic Kidney Disease (CKD) Drugs Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Chronic Kidney Disease (CKD) Drugs Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Antihypertensive
5.3.2. Antihyperlipidemic
5.3.3. Anemia Treatment Drugs
5.3.4. Swelling Treatment Drugs
5.3.5. Other


6. North America Chronic Kidney Disease (CKD) Drugs Market, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2022-2032, USD (Million)
6.3.Chronic Kidney Disease (CKD) Drugs Market: By Region, 2022-2032, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2022-2032, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2022-2032, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2022-2032, USD (Million)

7. UK and European Union Chronic Kidney Disease (CKD) Drugs Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2022-2032, USD (Million)
7.3.Chronic Kidney Disease (CKD) Drugs Market: By Region, 2022-2032, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2022-2032, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2022-2032, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2022-2032, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2022-2032, USD (Million)
7.3.1.5. France
7.3.1.5.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2022-2032, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2022-2032, USD (Million)

8. Asia Pacific Chronic Kidney Disease (CKD) Drugs Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2022-2032, USD (Million)
8.3.Chronic Kidney Disease (CKD) Drugs Market: By Region, 2022-2032, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2022-2032, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2022-2032, USD (Million)
8.3.1.3. India
8.3.1.3.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2022-2032, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2022-2032, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2022-2032, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2022-2032, USD (Million)

9. Latin America Chronic Kidney Disease (CKD) Drugs Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2022-2032, USD (Million)
9.3.Chronic Kidney Disease (CKD) Drugs Market: By Region, 2022-2032, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2022-2032, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2022-2032, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2022-2032, USD (Million)

10. Middle East and Africa Chronic Kidney Disease (CKD) Drugs Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2022-2032, USD (Million)
10.3.Chronic Kidney Disease (CKD) Drugs Market: By Region, 2022-2032, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2022-2032, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2022-2032, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2022-2032, USD (Million)

11. Company Profile
11.1. AbbVie, Inc.
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Allergan plc.
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. Amgen Inc.
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. AstraZeneca plc.
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. F. Hoffmann-La Roche Ltd
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. FibroGen
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. GlaxoSmithKline plc.
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. Johnson & Johnson
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. Keryx Biopharmaceuticals, Inc.
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. Kissei Pharmaceutical Co., Ltd
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives
11.11. Pfizer, Inc.
11.11.1. Company Overview
11.11.2. Financial Performance
11.11.3. Product Portfolio
11.11.4. Strategic Initiatives
11.12. Sanofi S.A.
11.12.1. Company Overview
11.12.2. Financial Performance
11.12.3. Product Portfolio
11.12.4. Strategic Initiatives
11.13. Teva Pharmaceutical Industries Ltd.
11.13.1. Company Overview
11.13.2. Financial Performance
11.13.3. Product Portfolio
11.13.4. Strategic Initiatives